Detailed price information for Bonesupport Holding Ab (BOEUF) from The Globe and Mail including charting and trades.

BONESUPPORT AB, an emerging leader in innovative injectable bioceramic bone scaffolds to treat bone voids caused by trauma, infection, disease or related surgery, announces that it has extended the ...

LUND, Sweden, March 23, 2020 /PRNewswire/ -- BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announced that the company will submit a De Novo application ...

Credit: Shutterstock. Cerament G is a resorbable, gentamicin-eluting ceramic bone void filler. The Food and Drug Administration (FDA) has cleared Cerament G for use as a bone void filler in skeletally ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An announcement from BONESUPPORT HOLDING ...

BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes the interim report for the first quarter 2026. "Solid start to 2026 - strong gro ...

Results from a new study, presented at the 33rd Annual Meeting of The European Bone & Joint Infection Society, showed complete wound healing in patients with chronic osteomyelitis treated with ...

* NEW PRECLINICAL DATA(1) HAS BEEN PUBLISHED THAT FURTHER SUPPORT BONESUPPORT'S AMBITION TO DEVELOP A COMBINATION PRODUCT OF COMPANY'S PLATFORM TECHNOLOGY CERAMENT® AND BISPHOSPHONATE, A ...

CERAMENT G is the first combination product which has successfully navigated the DeNovo process. To date, MCRA has supported 5 of the 9 orthopedic DeNovos granted by the U.S.FDA, including the first 3 ...

Please provide your email address to receive an email when new articles are posted on . BoneSupport has announced FDA market authorization of the Cerament G bone graft for patients with osteomyelitis, ...